Opendata, web and dolomites

CardAPcells

Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart”

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CardAPcells project word cloud

Explore the words cloud of the CardAPcells project. It provides you a very rough idea of what is the project "CardAPcells" about.

equity    fulfilment    rare    limited    threatening    insufficiency    acquired    stromal    clinical    multicenter    patients    therapies    plan    chronic    therapy    hospital    medicine    disease    usually    except    morbidity    preparation    spin    cells    efficacy    cardiac    bridge    achievements    atmp    suffer    exclusive    off    business    market    university    cellserve    cardap    artificial    heart    projected    competitors    cell    people    calculations    45    severe    criteria    germany    commercial    preparations    regulatory    donor    introduction    transferred    mortality    stress    worldwide    life    financing    charit    completely    therapeutic    cardiomyopathy    eacute    atmps    140    license    specialized    facilities    curative    regulation    mio    hearts    models    suffering    stem    fulfil    finalised    gmp    cure    approval    perform    die    advantages    trial    financial    progressive    area    solution    manufacturing    exemption    safety    preliminary    22   

Project "CardAPcells" data sheet

The following table provides information about the project.

Coordinator
CELLSERVE GMBH 

Organization address
address: CHARITEPLATZ 1
city: BERLIN
postcode: 10117
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.cellserve.de/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLSERVE GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

Chronic heart failure is a life-threatening disease usually without cure and a leading cause of morbidity and mortality. In Germany 45 000 patients (projected to EU: about 140 000) die every year from progressive chronic cardiac insufficiency. There is no curative therapeutic solution, except very rare donor hearts and artificial hearts as bridge devices. Researchers at the Charité - University Medicine, have identified unique cardiac-specific stromal cells (CardAP cells) with strong efficacy in cardiac stress models. CardAP cells are specialized heart-derived cells with key advantages in safety and efficacy. CardAP cells fulfil all criteria for cardiac cell therapy and cell product manufacturing has been transferred to GMP facilities. CellServe, a Charité spin off, will develop the CardAP cells for therapy of patients suffering from severe life-threatening cardiomyopathy. CellServe has acquired an exclusive license of this technology and will perform a clinical phase I/II study for patients with chronic cardiomyopathy. The technology of CellServe is completely distinct from all competitors, using specialized stromal heart cells and not stem cells.

CellServe has an experienced management in cell-based therapies area to develop and market ATMP products. It will apply for a so-called hospital exemption regulation, a limited preliminary approval, for early market introduction directly after the clinical study. Commercial potential: Worldwide 22 Mio people suffer from chronic cardiac insufficiency. 
 In Phase 1 a business plan for the CardAP cell product will be generated including financial calculations and the preparations for the clinical study will be finalised.
 Achievements Phase 2:
• Phase I/II clinical trial
• Approval for Hospital Exemption for ATMPs
• Preparation of a multicenter clinical trial
• Fulfilment of all regulatory requirements to perform a phase III clinical study
• Equity financing

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDAPCELLS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDAPCELLS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More